Native Lung Overinflation in Patients That Underwent Single Lung Transplantation Due to Emphysema
Conditions
Keywords
emphysema, lung transplantation
Brief summary
The purpose of the study is to investigate if bronchoscopic lung volume reduction by valves (Zephyr) would reduce native lung overinflation in patients that underwent single lung transplantation due to emphysema, and improve their well being and pulmonary function tests.
Detailed description
Emphysema is a progressive pulmonary disease characterized by abnormal and permanent enlargement of air spaces distal to terminal bronchioles accompanied by the destruction of pulmonary parenchyma. Treatment includes inhaled bronchodilator therapy, rehabilitation and/or oxygen treatment. In addition to the above, patients with severe emphysema may benefit from surgical lung volume reduction and/or lung transplantation. The rationale for lung volume reduction surgery is that reducing lung size would restore elastic recoil of the lung and improve chest wall and diaphragm mechanics. It has previously been shown that particularly patients with heterogeneous emphysema seem to benefit most from surgical lung volume reduction. Bronchoscopic lung volume reduction (BLVR) has recently been introduced as a less invasive potential alternative to surgical lung volume reduction. BLVR attempts to achieve the effects of surgery, by placing bronchial prostheses using a fibreoptic bronchoscope to selectively occlude the airways supplying the most affected hyperinflated regions of the emphysematous lung, while permitting exhaled gas to escape. This attempts to achieve segmental or lobar volume reduction, simulating the effects of surgical LVR. The purpose of the study is to investigate if bronchoscopic lung volume reduction by valves (Zephyr) would reduce native lung overinflation in patients that underwent single lung transplantation due to emphysema, and improve their well being and pulmonary function tests
Interventions
DEVICElung volume reduction using the Zephyr device
lung volume reduction using the Zephyr device
Sponsors
Rabin Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Single lung transplantation due to emphysema at least six months following transplantation that developed native lung overinflation * Age from 40 to 75 years * BMI \< 32 kg/m2 * FEV1 \< 40% of predicted value, FEV1/FVC \< 70% * TLC \> 120% predicted, RV \> 150% predicted. * Stable with \< 20 mg prednisone (or equivalent) qd * PaCO2 \< 50mm Hg * PaO2 \> 45 mm Hg on room air * 6-min walk of \> 50m (without rehabilitation) or \> 100m (with rehabilitation) * Nonsmoking for 4 months prior to initial interview and throughout screening * The patient agrees to all protocol required follow-up intervals. * The patient has no child bearing potential * The patient is willing and able to complete protocol required baseline assessments and procedures
Exclusion criteria
* Prior endobronchial treatment for emphysema * Pleural or interstitial disease that precludes surgery. * Prior lung transplant, LVRS, median sternotomy, bullectomy or lobectomy. * Clinically significant bronchiectasis * Pulmonary nodule requiring surgery * History of recurrent respiratory infections (\> 3 hospitalization in the last year) * Clinically significant (\> 4 Tablespoons per day) sputum production * Fever, elevated white cell count, or other evidence of active infection * Dysrhythmia that might pose a risk during exercise or training * Congestive heart failure within 6 mo and LVEF \< 45% * Evidence or history of Cor Pulmonale * Resting bradycardia (\< 50 beats/min), frequent multifocal PVCs, complex ventricular arrhythmia, sustained SVT * History of exercise-related syncope * MI within 6 mo and LVEF \< 45% * Evidence of systemic disease or neoplasia expected to compromise survival during 5-yr period * Any disease or condition that interferes with completion of initial or follow-up assessments * Patient is currently enrolled in another clinical trial * Patient is unable to complete 3 minutes of unloaded peddling on cycle ergometer * Alpha-1-Antitrypsin Deficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •Mean % change in lung function (FEV1) | 90 days |
Secondary
| Measure | Time frame |
|---|---|
| Mean change in six minutes walk distance | 90 days |
Countries
Israel
Contacts
Primary ContactMordechai Kramer Kramer, MD
Outcome results
None listed